by chemicalroute | Oct 2, 2025 | Uncategorized
Key Notes 1P-LSD is a prodrug of LSD, so most risks mirror LSD: acute anxiety, perceptual changes, tachycardia, and rare persistent visual phenomena (1, 2, 3). Highest risk contexts: unknown purity/dose, mixing with other substances (especially stimulants, MAOIs, or...
by chemicalroute | Sep 28, 2025 | Uncategorized
Key Notes 1P-LSD is a prodrug of LSD, converting into LSD in the body [(1)]. Mechanism: primarily 5-HT2A receptor agonism, with secondary roles for 5-HT1A, 5-HT2C, dopamine D2, and adrenergic receptors [(2), (3)]. Potential therapeutic domains: depression, anxiety,...
by chemicalroute | Sep 24, 2025 | Uncategorized
Key Notes 1P-LSD is increasingly restricted though not universally scheduled. Europe: Germany (NpSG), UK (Psychoactive Substances Act), and Denmark explicitly ban it [(1)]. US: Not scheduled, but at risk under the Federal Analogue Act [(2)]. Canada: Unscheduled but...
by chemicalroute | Sep 23, 2025 | Uncategorized
Quick Overview 1P-LSD is a prodrug of LSD: it rapidly hydrolyzes to LSD in human serum, confirmed by LC-MS/MS (1). Primary mechanism: LSD’s 5-HT2A partial agonism drives the hallmark perceptual and cognitive changes (2). Secondary targets: 5-HT1A/2C (mood/affect),...
Recent Comments